

Tuberculosis (TB) diagnostics are needed to detect exposure, diagnose disease and drug resistance, and to monitor improvement under treatment in both primary healthcare and laboratory settings. The Foundation for Innovative New Diagnostics (FIND) and the Stop TB Partnership's New Diagnostics Working Group (NDWG) bring to you the latest developments in TB diagnostics R&D. You will hear from leading global experts on the advancements in the TB diagnostics pipeline, improvements in the detection of drug-resistant TB, next-generation sequencing and the diagnosis of TB infection.

Introduction by session Chairs

Daniela Maria Cirillo, OSR & NDWG

Nazir Ismail, WHO & NDWG

18:15-18:20

Presentations

TB diagnostics pipeline update – 2020 and beyond

Morten Ruhwald, FIND & NDWG

Recent advances in the diagnosis of drug-resistant TB

18:40–18:50

Adam Penn-Nicholson, FIND
Seg&Treat – bringing next-generation TB care to

18:50-19:00

underserved communities

Anita Suresh, FIND

Improving interpretation of pncA gene mutations for sequencing-based drug susceptibility testing of pyrazinamide

19:00-19:10

Paolo Miotto, OSR & NDWG

Advancing the TB prevention agenda

19:10-19:20

Alberto Matteelli, University of Brescia & NDWG

Closing remarks + Q&A

facilitated by session Chairs

19:20-19:45

Daniela Maria Cirillo, OSR & NDWG Nazir Ismail, WHO & NDWG

FIND Because diagnosis matters

*Participants registered to the conference can attend the session

Stop B Partnership